News Image

Boundless Bio Announces Pipeline and Leadership Updates

Provided By GlobeNewswire

Last update: Dec 12, 2024

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial

Third ecDTx program advancing, with plans for development candidate nomination by mid-2025

Read more at globenewswire.com

BOUNDLESS BIO INC

NASDAQ:BOLD (12/12/2025, 5:19:22 PM)

After market: 1.16 -0.01 (-0.85%)

1.17

+0.02 (+1.74%)



Find more stocks in the Stock Screener

Follow ChartMill for more